PaulBChapmanMD

Hematologic Oncology

Attending Physician, Memorial Sloan Kettering Cancer Center. Professor of Medicine, Cornell University-Weill Medical College

Join to view full profile

Dr. Chapman is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Chapman's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10021
Phone(646) 888-4162
Is this information wrong?

Education & Training

Memorial Sloan-Kettering Cancer CenterFellowship, Immunology, 1984 - 1988
University of ChicagoResidency, Internal Medicine, 1981 - 1984
Weill Cornell Medical College of Cornell UniversityClass of 1981

Certifications & Licensure

NJ State Medical License 2020 - 2021
NY State Medical License 1988 - 2022
IL State Medical License 1981 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Molecularly Targeted Therapy in Treating Patients With Melanoma That is Metastatic or Cannot be Removed by Surgery Start of enrollment: 2014 May 01Bryce, A.H.,Cowey, C.L.,Lao, C.D.,Zuccaro, C.,Schwartz, G.K.,Tawbi, H.A.,Sosman, J.A.,Forman, K.,Fecher, L.A.,LoRusso, P.,Chapman, P.B.,Joseph, R.W.,Ejadi, S.,Markovic, S.N.
CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma Start of enrollment: 2014 Apr 01Hanks, B.A.,Ernstoff, M.S.,Bhardwaj, N.,Chapman, P.B.
A Phase 2 Trial of the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation Start of enrollment: 2013 Jul 01Chapman, P.B.
A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation Start of enrollment: 2012 Sep 01Chapman, P.B.
A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation Start of enrollment: 2011 Nov 01Chapman, P.B.
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma Start of enrollment: 2009 Apr 01Chapman, P.
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2009 Mar 01Chapman, P.
Pilot Trials With a KLH Conjugated Bivalent GangliosideVaccine Mixed With Immunological Adjuvants QS-DG or OPT-821in Patients With Disease Free AJCC Stage III or IV Start of enrollment: 2007 Dec 01Chapman, P.
A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT Start of enrollment: 2007 Apr 01Carvajal, R.,Chapman, P.B.,Chmielowski, B.,Kaufman, H.L.,Lutzky, J.,Pavlick, A.,Rothschild, N.E.,Schwartz, G.K.,Shore, T.B.
A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain Start of enrollment: 2007 Mar 01Abrey, L.E.,Chapman, P.B.,Motzer, R.J.
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection Start of enrollment: 2005 Sep 01Chapman, P.
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma Start of enrollment: 2005 Jan 01Chapman, P.
Phase II Trial Of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Diluted In EPL Diluent (NSC #704057) In Metastatic Melanoma Patients Start of enrollment: 2004 Jun 01Chapman, P.B.
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01Wolchok, J.D.,Chapman, P.B.
Pilot Trial of Multi-Epitope Melanoma Peptide Vaccine Using GM-CSF, Montanide and QS-21 as Adjuvants Start of enrollment: 1998 May 01Chapman, P.B.
Phase I-II Trial of High-Dose Acetaminophen With Carmustine in Patients With Metastatic Melanoma Start of enrollment: 1997 Nov 01Chapman, P.B.
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery Paul Chapman, MD
Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma Paul Chapman, MD
Join now to see all

Publications & Presentations

PubMed

Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
James W. Smithy, Matthew J. Pianko, Colleen Anne Maher, Michael A. Postow, Alexander N. Shoushtari, Parisa Momtaz, Paul B. Chapman, Jedd D. Wolchok, Jae H. Park, Marga...> ;Journal of Immunotherapy. 2021 Jan 1
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
F. Stephen Hodi, Paul B. Chapman, Mario Sznol, Christopher D. Lao, Rene Gonzalez, Michael Smylie, Gregory A. Daniels, John A. Thompson, Ragini R. Kudchadkar, William H...> ;Melanoma Research. 2020 Nov 23
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.
Bielski, C. M., Donoghue, M. T., Gadiya, M., Hanrahan, A. J., Won, H. H., Chang, M. T., Jonsson, P., Penson, A. V., Gorelick, A., Harris, C., Schram, A. M., Syed, A., ...> ;Cancer cell. 2018 Nov 6
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio, Karl D. Lewis, Lev V. Demidov, Mario Mandalà, Igor Bondarenko, Paolo A. Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Gum...> ;Lancet Oncology. 2018 Apr 1
Changing the Standard of Care for Treating Melanoma Brain Metastases
Paul Chapman, MD> ;The Lancet. 2018 Apr 1
1 citation
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
Carvajal, R. D., Piperno-Neumann, S., Kapiteijn, E., Chapman, P. B., Frank, S. J., Joshua, A. M., Piulats, J. M., Wolter, P., Cocquyt, V., Chmielowski, B., Evans, T. R...> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 13
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Samuel Rosner, Erica Kwong, Alexander N. Shoushtari, Claire F. Friedman, Allison S. Betof, Mary Sue Brady, Daniel G. Coit, Margaret K. Callahan, Jedd D. Wolchok, Paul ...> ;Cancer Medicine. 2018 Mar 1
2 citations
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.
Jasmine H. Francis, Larissa A. Habib, David H. Abramson, Lawrence A. Yannuzzi, Murk-Hein Heinemann, Mrinal M. Gounder, Rachel N. Grisham, Michael A. Postow, Alexander ...> ;Ophthalmology. 2017 Dec 1
1 citation
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
Algazi, A. P., Esteve-Puig, R., Nosrati, A., Hinds, B. R., Hobbs-Muthukumar, A., Nandoskar, P., Ortiz-Urda, S., Chapman, P. B., Daud, A.> ;Pigment cell & melanoma research. 2017 Sep 19
3 citations
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
Shoushtari, A. N., Friedman, C. F., Navid-Azarbaijani, P., Postow, M. A., Callahan, M. K., Momtaz, P., Panageas, K. S., Wolchok, J. D., Chapman, P. B.> ;JAMA oncology. 2017 Aug 18
PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma
Federica Catalanotti, Donavan T. Cheng, Alexander N. Shoushtari, Douglas B. Johnson, Katherine S. Panageas, Parisa Momtaz, Catherine F. Higham, Helen Won, James J. Har...> ;JCO precision oncology. 2017 Jun 23
Systemic Therapy Options for Patients With Unresectable Melanoma.
Yushak, M.,Chapman, P.,Robert, C.,Kudchadkar, R.> ;Am Soc Clin Oncol Educ Book. 2017 May 01
A step forward for patients with NRAS-mutant melanoma.
Postow, M. A., Chapman, P. B.> ;The Lancet. Oncology. 2017 Mar 13
Patient perspectives on ipilimumab across the melanoma treatment trajectory.
Shuk, E., Shoushtari, A. N., Luke, J. J., Postow, M. A., Callahan, M., Harding, J. J., Roth, K. G., Flavin, M., Granobles, A., Christian, J., Gold, G. S., Schoenhammer...> ;Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017 Mar 2
4 citations
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
Koetz-Ploch, L., Hanniford, D., Dolgalev, I., Sokolova, E., Zhong, J., Díaz-Martínez, M., Bernstein, E., Darvishian, F., Flaherty, K. T., Chapman, P. B., Tawbi, H., He...> ;Pigment cell & melanoma research. 2017 Feb 1
3 citations
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.
Friedman, C. F., Friedman, C. F., Clark, V., Clark, V., Raikhel, A. V., Raikhel, A. V., Barz, T., Barz, T., Shoushtari, A. N., Shoushtari, A. N., Momtaz, P., Momtaz, P...> ;Journal of the National Cancer Institute. 2017 Jan 4
Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
Peinado H, Alecˇković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM, Nitadori-Hoshino A, Hoffman ...> ;Nat. Med.. 2016-12-06
2 citations
Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.
Lee, A. Y., Droppelmann, N., Panageas, K. S., Zhou, Q., Ariyan, C. E., Brady, M. S., Chapman, P. B., Coit, D. G.> ;Annals of surgical oncology. 2016 Nov 3
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, Munhoz RR, Buchar G, Hester RH, Romero JA, Fitzpatrick LJ, Weiser MR, Panageas KS, Wolchok JD, C...> ;Melanoma Res.. 2016-10-27
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
Shoushtari AN, Ong LT, Schoder H, Singh-Kandah S, Abbate KT, Postow MA, Callahan MK, Wolchok J, Chapman PB, Panageas KS, Schwartz GK, Carvajal RD> ;Melanoma Res.. 2016-06-01
1 citation
Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib
Paul Chapman, MD> ;Clinical Cancer Research. 2015 Oct 23
Reply to A. Indini et al.
Horvat, T. Z., Adel, N. G., Dang, T., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., Panageas, K. S., Wolcho...> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Jan 21
Safety of Infusing Ipilimumab Over 30 Minutes.
Momtaz P, Park V, Panageas KS, Postow MA, Callahan M, Wolchok JD, Chapman PB> ;J. Clin. Oncol.. 2015-10-20
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilim...
Horvat TZ, Adel NG, Dang T, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB> ;J. Clin. Oncol.. 2015-10-01
1 citation
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Amaravadi, R. K., Hamilton, K. E., Ma, X., Piao, S., Del Portillo, A., Nathanson, K. L., Carlino, M. S., Long, G. V., Puzanov, I., Xu, X., Morrissette, J. J., Tsai, K....> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jul 24
Join now to see all

Press Mentions

Merck’s Proposed Less Frequent Keytruda Dosing May Allow for Minor Uptake BoostNovember 21, 2019 02:53
Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma PatientsJune 22, 2019 22:44
Long-Term Outcomes of Dabrafenib/Trametinib in BRAF V600–Mutated Advanced MelanomaJune 10, 2019 23:17
Join now to see all